[
  {
    "indication": "oral fabhalta (iptacopan), the first and only treatment approved in c3 glomerulopathy",
    "approval_date": "2025-03-21",
    "year": 2025,
    "confidence": "high",
    "source_text": "Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment App"
  },
  {
    "indication": "fabhalta (iptacopan) for the reduction of proteinuria in primary iga nephropathy (igan)",
    "approval_date": "2024-08-08",
    "year": 2024,
    "confidence": "high",
    "source_text": "Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan) for the Reduction of Proteinuria"
  },
  {
    "indication": "adults with paroxysmal nocturnal hemoglobinuria (pnh)",
    "approval_date": "2023-12-06",
    "year": 2023,
    "confidence": "high",
    "source_text": "FDA Approves Fabhalta (iptacopan) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinur"
  }
]